Obtained results showed the target-specific killing of CD19+ T cell lymphoma cells in vitro (over 50% dead cells in 1:1 ratio up to 85% dead cells in 10:1 ratio) as well as inhibited tumor progression in vivo (<1000 mm3 vs >1500 mm3 tumor volume in controls). The gene discussed is CD19; the disease is neoplasm.